MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bjh.15819

Медицинская библиотека · British journal of haematology · 2019

Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia.

Kröger Nicolaus, Eikema Diderik-Jan, Köster Linda, Beelen Dietrich, de Wreede Liesbeth C, Finke Jürgen, Koenecke Christian, Niederwieser Dietger, Bornhäuser Martin, Schoenland Stefan, Potter Victoria, Wolschke Christine, Maertens Johan, Theobald Matthias, Kobbe Guido, Itälä-Remes Maija, Wulf Gerald, Kahls Peter, Forcade Edouard, Greinix Hildegard, Masszi Tamás, Yakoub-Agha Ibrahim, Chalandon Yves, Robin Marie, Chronic Malignancies Working Party of the European Society for Blood Marrow Transplantation

СтатьяПеревод в очереди

Аннотация

Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and chronic myelomonocytic leukaemia (CMML) can progress to secondary acute myeloid leukaemia (sAML). We compared the outcome of 4214 sAML patients who received allogeneic haematopoietic stem cell transplantation (allo-HSCT) from an unrelated (62%) or human leucocyte antigen (HLA)-identical sibling donor (38%) according the underlying disease: MDS (n = 3541), CMML (n = 251) or MPN (n = 422). After a median follow up of 46·5 months, the estimated 3-year progression-free (PFS) and overall survival (OS) for the entire group was 36% (34-37%) and 41% (40-43%), respectively. The cumulative incidence of relapse and non-relapse mortality (NRM) was 37% (35-39%) and 27% (26-29%), respectively. In a multivariable analysis for OS, besides age (P < 0·001), unrelated donor (P = 0·011), cytomegalovirus ± constellation (P = 0·007), Karnofsky index ≤ 80 (P < 0·001), remission status (P < 0·001), peripheral blood as stem cell source (P = 0·009), sAML from MPN (P = 0·003) remained a significant factor in comparison to sAML from MDS, while worse outcome of sAML from CMML did not reach statistical significance (P = 0·06). This large registry study demonstrates a major impact of the underlying disease on outcome of sAML after allo-HSCT.

Для цитирования: Kröger Nicolaus, Eikema Diderik-Jan, Köster Linda, Beelen Dietrich, de Wreede Liesbeth C, Finke Jürgen, Koenecke Christian, Niederwieser Dietger, Bornhäuser Martin, Schoenland Stefan, Potter Victoria, Wolschke Christine, Maertens Johan, Theobald Matthias, Kobbe Guido, Itälä-Remes Maija, Wulf Gerald, Kahls Peter, Forcade Edouard, Greinix Hildegard, Masszi Tamás, Yakoub-Agha Ibrahim, Chalandon Yves, Robin Marie, Chronic Malignancies Working Party of the European Society for Blood Marrow Transplantation. Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia.. British journal of haematology. 2019. DOI: 10.1111/bjh.15819.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.